CARDIO-SIMDOX

The CARDIO-SIMDOX project aims to investigate the cardioprotective role of Simvastatin in cancer patients treated with Doxorubicin, a highly effective chemotherapy agent limited by severe heart-related side effects. Cardiotoxicity, worsened by pre-existing conditions such as hypertension or diabetes, is now recognized as a continuous process driven by oxidative stress and inflammation. Given the limitations of Dexrazoxane, the only FDA-approved cardioprotective drug, the project explores the repurposing of Simvastatin - commonly used to reduce cholesterol - for its additional anti-inflammatory and antioxidant properties. Through a combination of in vitro studies and clinical data analysis, CARDIO-SIMDOX brings together expertise in molecular biology, pharmacology, oncology, and cardiology to develop innovative strategies that improve the quality of life for cancer patients and make Italy a key player in drug-induced cardiotoxicity research.